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Background: Controversy persists regarding the efficacy and safety of pre-operative clopidogrel use in patients with non-ST-segment elevation 
acute coronary syndrome (NSTE-ACS) requiring coronary artery bypass grafting (CABG). We conducted a meta-analysis of clinical trials to evaluate 
the impact of clopidogrel use in the above setting.
Methods: We performed a systematic search for studies comparing death, re-operation for bleeding and packed red blood cell (PRBC) transfusion 
in patients exposed (Group A) versus not exposed (Group B) to clopidogrel within 5 days of CABG in the setting of NSTE-ACS. Five trials with 7212 
patients were included. Relative risks (RR) and 95% confidence intervals (CI) were computed. A two-sided alpha error of < 0.05 was considered as 
statistically significant (p<0.05).
Results: Compared with group B (figure below), the risk of death (RR,1.165; 95% CI, 0.835 to 1.626; P= 0.368) and re-operation for bleeding (RR, 
0.674; 95% CI, 0.284 to 1.598; P= 0.37) was similar in Group A. However, PRBC transfusion (RR, 1.124; 95% CI, 1.061 to 1.190, P= 0.00) was more 
in group A compared to group B.
Conclusions: In NSTE-ACS patients undergoing CABG, clopidogrel exposure within 5 days of surgery has no impact on the need for re-operation 
due to bleeding or mortality compared to clopidogrel unexposed patients. However, there is a significant increase in the requirement for PRBC 
transfusion in patients exposed to clopidogrel within 5 days of surgery.
